IRCT20180103038199N9尚未招募2 期
Formulation and clinical evaluation (Phase 2 clinical trial) of complementary therapy with b-Caryophyllene in osteoarthritis patients: determination of effectiveness and safety
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40 years 至 70 years（—）
- 性别
- All
入选标准
- •Lack of proper response (having a score higher than 30 on the VAS numerical-visual scale at the beginning of the study) to the analgesic drug meloxicam after at least two weeks of drug administration before the start of the study
- •Age between 40-70 years old
- •Patients with BMI lower than 37
排除标准
- •Patient's dissatisfaction with continued cooperation during the study
- •Need to perform any new therapeutic interventions during the study period
- •Active liver or kidney disease and malignancies
- •Secondary or suspected osteoarthritis
- •Patients treated with hormonal medicines
- •Patients treated with anticoagulants
- •Patients with a history of ischemic or hemorrhagic stroke
- •Patients with a history of deep vein thrombosis
- •Treatment with oral corticosteroids 4 weeks before the start of the study
- •Intra-articular injection of hyaluronic acid three months before the start of the study
- •Patients who have had intra-articular corticosteroid injections in the last 4 weeks
研究者
相似试验
已完成
2 期
Phase II study to evaluate pharmacodynamics, pharmacokinetics and safety after cyclic dose or continuous dose of FSN-013 for 3 cycles in Japanese healthy adult female subjectsdysmenorrheaJPRN-jRCT2080223983Fuji Pharma Co., Ltd.60
Unknown
1 期
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding DisordersCTRI/2021/03/032089Catalyst Biosciences Inc8
进行中（未招募）
1 期
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog alfa (activated) in Treatment of Episodic Bleeding in Subjects with Factor VII deficiency, Glanzmann thrombasthenia, and Haemophilia A with inhibitors on prophylaxisFactor VII deficiency, Glanzmann thrombasthenia (GT) and Hemophilia A with inhibitors on emicizumab prophylaxis (HAwI-E)MedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: PTClassification code 10016079Term: Factor VII deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003371-18-ITCatalyst Biosciences, Inc.24
招募中
2 期
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3GIgA NephropathyLupus Nephritis (LN)C3 (Complement Component 3) GlomerulopathyNCT06419205Akebia Therapeutics30
已完成
1 期
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic MalignanciesHematologic NeoplasmsNCT02329847Janssen Research & Development, LLC144